Annexon prioritizes 4 flagship complement programs; GBS Phase 3 enrollment expanded to 220 patients

Annexon, Inc.

ANX005 Phase 3 in GBS expanded to 220 patients; pivotal data expected H1 2024.
ANX005 Phase 2/3 pivotal in Huntington's to initiate in 2023.
ANX007 Phase 2 in geographic atrophy on track for initial data mid-2023.
Cash $269.5M as of Sep 30, 2022; operating runway updated to into 2025.
Deprioritizing wAIHA; advancing ANX1502 (oral small molecule) into MAD study H1 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.